IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) and Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.
Insider and Institutional Ownership
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares IDEAYA Biosciences and Bolt Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IDEAYA Biosciences | -75.93% | -16.73% | -15.34% |
| Bolt Biotherapeutics | -611.47% | -126.23% | -54.70% |
Analyst Recommendations
This is a summary of recent recommendations for IDEAYA Biosciences and Bolt Biotherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IDEAYA Biosciences | 1 | 1 | 13 | 0 | 2.80 |
| Bolt Biotherapeutics | 1 | 1 | 2 | 0 | 2.25 |
IDEAYA Biosciences currently has a consensus price target of $50.55, indicating a potential upside of 59.75%. Bolt Biotherapeutics has a consensus price target of $14.50, indicating a potential upside of 132.37%. Given Bolt Biotherapeutics’ higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than IDEAYA Biosciences.
Earnings and Valuation
This table compares IDEAYA Biosciences and Bolt Biotherapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IDEAYA Biosciences | $218.71 million | 12.71 | -$113.70 million | ($1.94) | -16.31 |
| Bolt Biotherapeutics | $7.70 million | 1.56 | -$33.38 million | ($16.44) | -0.38 |
Bolt Biotherapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
IDEAYA Biosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Summary
IDEAYA Biosciences beats Bolt Biotherapeutics on 9 of the 13 factors compared between the two stocks.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
